ALTREN® (ALTRENOGEST)

Altren® (altrenogest) Solution 0.22% is indicated to suppress estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.

Product Features

The cost-effective alternative to Regu-Mate®
The same active ingredient as Regu-Mate®
Use to schedule estrus in mares and breeding in mares to maximize breeding efficiency
Available in 1000 mL and 150 mL bottles along with FDA-approved vented draw-off cap. Administer orally with dose syringe or by placing directly on feed
Provides safe, effective suppression of estrus in mares – 95% effective after 3 days of treatment

Package presentation	Available
1,000 mL Bottle	Reorder No: 28006
150 mL Bottle	Reorder No: 28007

Clicking a link on this page will open a PDF file in a new window.

Regu-Mate is a Registered Trademark of Merck Animal Health.

IMPORTANT SAFETY INFORMATION:

Altren® is contraindicated for use in mares having a previous or current history of uterine inflammation. Natural or synthetic gestagen therapy may exacerbate existing low-grade or “smoldering” uterine inflammation into a fulminating uterine infection in some instances. Do not use in horses intended for human consumption. Avoid skin contact. Altren® is absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. Wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®, or when touching contaminated surfaces or equipment. Latex gloves are not protective. PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE ALTREN®. WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT. Altren® is readily absorbed through the skin and could lead to a disruption of the menstrual cycle or prolongation of pregnancy. People who should not handle this product include those with thrombophlebitis, thromboembolic disorders, or with a history of these events, cerebral-vascular or coronary-artery disease, suspected estrogen-dependent neoplasia, benign or malignant tumors which developed during the use of oral contraceptives or other estrogen containing products, liver dysfunction or disease, and women with known or suspected carcinoma of the breast or undiagnosed vaginal bleeding. Accidental spillage on the skin should be washed off immediately with soap and water. Keep out of the reach of children. For complete safety information, refer to the product label.

PRECAUTIONS:

Various synthetic progestins, including altrenogest, when administered to rats during the embryogenic stage of pregnancy at doses manyfold greater than the recommended equine dose caused fetal anomalies, specifically masculinization of the female genitalia.

WARNINGS:

Altren® (altrenogest) Solution 0.22% is readily absorbed by the skin. Skin contact must be avoided; protective gloves must be worn when handling this product. Not for use in humans. Keep out of reach of children. Altren® is absorbed through unbroken skin, and exposure may result in serious side effects to both women and men.